High-on Clopidogrel Platelet Reactivity as Assessed by Thromboelastography in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.

High-on Clopidogrel Platelet Reactivity as Assessed by Thromboelastography in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. - HPR TEG-AF PCI

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00024509

Enrollment

166

Registered

2021-07-21

Start date

2021-06-03

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I21 I25 I26

Interventions

Group 1: Patients will be divided in two groups according to the results of thrombelastographie. Group A: high on Clopidogrel defined as patients with maximum amplitude of ADP induced platelet aggreg

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: - Informed consent - Age of =18 - Atrial fibrillation/flutter with an indication for permanent anticoagulation therapy (i.e. CHA2DS2VASC =1 for man and CHA2DS2VASC =2 for women) - Percutaneous coronary intervention in the previous 3 days

Exclusion criteria

Exclusion criteria: Exclusion criteria: - Contraindication for Clopidogrel intake - History of stent-thrombosis - Patient not suitable for inclusion in the study (e.g. incompliance, drug abuse, unwillingness to adhere to the protocol) - GPIIb/IIIa inhibition within the last 24h - Use of Prasugrel or Ticagrelor within the last 7 days - Less than 50 thousand platelets per µl blood

Design outcomes

Primary

Measure	Time frame
It is a composite endpoint of all-cause death, myocardial infarction or stroke at 6 months.	—

Secondary

Measure	Time frame
• Bleedings (major or non-major clinically relevant) as defined by the International Society on Thrombosis and Haemostasis (ISTH) after 180 days. • Assessment of other possible exploratory markers: o Immature platelet fraction o CYP2C19 genotyping o Anti-Factor Xa/II activity o from ClotPro o Fibrinogen	—

Countries

Germany

Contacts

Public ContactDiona Gjermeni

Kardiologie und Angiologie

diona.gjermeni@uniklinik-freiburg.de004917627034010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026